Discover why Rhythm Pharmaceuticals, Inc. earns a strong buy as IMCIVREE expands in rare obesity markets. Click for this ...

As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition ...

Precigen is a Buy after PAPZIMEOS' FDA approval and strong launch, with high pricing and growth potential. Click here to read ...

As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition, offering a balance of durable clinical responses and acceptable ...

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with ...

AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...

For decades, one of the most widely prescribed pregnancy drugs has been used on faith: doctors knew it helped sustain early ...

Novo Nordisk NVO reported disappointing top-line data from the two-year primary analysis of two late-stage studies evaluating ...

Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene ...

The Global Medium Chain Triglycerides Market Size is projected to grow at a CAGR of 8.14% from 2026 to 2032, according to a new report published by Verified Market Research®. The report reveals that ...

Major stock indexes ended sharply higher Monday to begin a holiday-shortened trading week, with investors increasingly confident the Federal Reserve will cut interest rates at its December meeting.

Selinexor-based regimens enhance T-cell activation in RRMM patients, without increasing inhibitory checkpoint molecules, indicating resistance is not due to T-cell exhaustion. Baseline protein ...